Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557215 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of Rifaximin With NAC in IBS-D
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04557215 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT04557215, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Randomized, prospective proof of concept, double-blind, single site clinical trial to determine the efficacy of combined rifaximin and N-acetylcysteine (NAC) therapy vs. rifaximin alone in decreasing clinical symptoms in subjects with IBS-D.
Interventions
- DRUG Placebo
- DRUG Rifaximin
- DRUG N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2022-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557215
The ClinicalTrials.gov registry entry for NCT04557215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04557215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04557215 about?
NCT04557215 is a clinical study titled "Efficacy and Safety of Rifaximin With NAC in IBS-D". Randomized, prospective proof of concept, double-blind, single site clinical trial to determine the efficacy of combined rifaximin and N-acetylcysteine (NAC) therapy vs. rifaximin alone in decreasing clinical symptoms in subjects with IBS-D.
What is the current status of trial NCT04557215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-11-13. Estimated completion is 2022-10-30.
What interventions are being tested in trial NCT04557215?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG), N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT04557215?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.